ReviewProstate cancer and prostatic diseases2022
The microbiome and prostate cancer.
Review in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Urinary microbiota and prostatic diseases: the key for the lock? A systematic review.Prostate cancer and prostatic diseases · 2023Pooled it
- Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?The Journal of pathology · 2026Review
- Associations of oral microbiome diversity with prevalent cancer: a population-based cross-sectional study.Archives of microbiology · 2026Article
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Microbial Genomic Consortia in Prostate Cancer: Mechanistic Signaling, the Gut-Prostate Axis, and Translational Perspectives.Cancers · 2026Review
- Dysbiosis-Mediated Regulation of Stem Cells the First Hit for Cancer Generation.International journal of molecular sciences · 2026Review
- Human papillomavirus in prostate cancer: examining the evidence for a co-factor role.Frontiers in microbiology · 2026Review
- Research progress and clinical translation prospects of the urinary tract microbiome in prostate cancer.Frontiers in immunology · 2026Review
- Adaptation of MALDI-TOF MS Technique for Tracking Changes in the Urinary Microbiome During and After Radiotherapy for Prostate Cancer.Cancer management and research · 2026Article
- Decoding Microbiome's Role in Prostate Cancer Progression and Treatment Response.Diseases (Basel, Switzerland) · 2025Review
- The association between urinary nitrate and prostate specific antigen without prostatic disease: a cohort study.BMC urology · 2025Article
- Nutrition and Diet in the Prevention and Management of Prostate Cancer in Mexico: A Narrative Review.Nutrients · 2025Review
- Reprogramming prostate cancer through the microbiome.Frontiers in medicine · 2025Review
- The bacterial microbiome and cancer: development, diagnosis, treatment, and future directions.Clinical and experimental medicine · 2024Review
- Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.Molecular cancer · 2024Review
- PDIA2 is associated with the prognosis of prostate cancer, and downregulation of PDIA2 delays the progression of prostate cancer cells.Scientific reports · 2024Article
- Cancer and the Microbiome of the Human Body.Nutrients · 2024Review
- Microbiome Dysbiosis Is Associated with Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer.International journal of molecular sciences · 2024Article
- Gut microbiome-metabolome interactions predict host condition.Microbiome · 2024Article
- Prostate Cancer and the Mevalonate Pathway.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
There is growing evidence that the microbiome is involved in development and treatment of many human diseases, including prostate cancer. There are several potential pathways for microbiome-based mechanisms for the development of prostate cancer: direct impacts of microbes or microbial products in the prostate or the urine, and indirect impacts from microbes or microbial products in the gastrointestinal tract. Unique microbial signatures have been identified within the stool, oral cavity, tissue, urine, and blood of prostate cancer patients, but studies vary in their findings. Recent studies describe potential diagnostic and therapeutic applications of the microbiome, but further clinical investigation is needed. In this review, we explore the existing literature on the discovery of the human microbiome and its relationship to prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.